| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,630,000 |
| Market
Cap: |
28.43(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$174.72 - $321.36 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
203,730 |
1,415,939 |
20,560,280 |
21,776,425 |
| Total Sell Value |
$57,617,287 |
$368,793,599 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
7 |
8 |
9 |
11 |
| Total Sell Transactions |
26 |
40 |
60 |
80 |
| End Date |
2025-05-25 |
2025-02-21 |
2024-08-23 |
2023-08-24 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wu Xiaobin |
President and COO |
• – – |
2025-08-14 |
4 |
AS |
$300.86 |
$12,182,818 |
D/D |
(39,936) |
0 |
|
1% |
|
| Wu Xiaobin |
President and COO |
• – – |
2025-08-14 |
4 |
OE |
$155.68 |
$6,247,989 |
D/D |
39,936 |
39,936 |
|
- |
|
| Lee Chan Henry |
SVP, General Counsel |
• – – |
2025-08-13 |
4 |
AS |
$300.00 |
$3,308,877 |
D/D |
(11,013) |
0 |
|
2% |
|
| Lee Chan Henry |
SVP, General Counsel |
• – – |
2025-08-13 |
4 |
OE |
$159.03 |
$1,464,080 |
D/D |
8,230 |
8,230 |
|
- |
|
| Wu Xiaobin |
President and COO |
• – – |
2025-08-13 |
4 |
AS |
$300.33 |
$15,164,818 |
D/D |
(49,858) |
0 |
|
2% |
|
| Wu Xiaobin |
President and COO |
• – – |
2025-08-13 |
4 |
OE |
$155.68 |
$8,188,887 |
D/D |
49,858 |
49,858 |
|
- |
|
| Rosenberg Aaron |
Chief Financial Officer |
• – – |
2025-08-01 |
4 |
S |
$290.47 |
$345,659 |
D/D |
(1,190) |
0 |
|
-5% |
|
| Lee Chan Henry |
SVP, General Counsel |
• – – |
2025-07-30 |
4 |
S |
$304.60 |
$280,233 |
D/D |
(920) |
0 |
|
-5% |
|
| Wang Lai |
Global Head of R&D |
• – – |
2025-07-30 |
4 |
AS |
$305.00 |
$78,995 |
I/I |
(259) |
0 |
|
5% |
|
| Wang Lai |
Global Head of R&D |
• – – |
2025-07-29 |
4 |
AS |
$302.00 |
$1,222,380 |
I/I |
(4,041) |
259 |
|
3% |
|
| Wang Lai |
Global Head of R&D |
• – – |
2025-07-18 |
4 |
AS |
$300.00 |
$210,000 |
I/I |
(700) |
0 |
|
6% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2025-07-09 |
4 |
AS |
$252.23 |
$7,044,591 |
D/D |
(27,802) |
0 |
|
23% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2025-06-24 |
4 |
AS |
$263.50 |
$532,867 |
D/D |
(2,007) |
0 |
|
18% |
|
| Wu Xiaobin |
President and COO |
• – – |
2025-06-23 |
4 |
S |
$260.00 |
$354,380 |
D/D |
(1,363) |
0 |
|
-22% |
|
| Wang Lai |
Global Head of R&D |
• – – |
2025-06-23 |
4 |
S |
$260.00 |
$267,280 |
D/D |
(1,028) |
0 |
|
-22% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2025-06-23 |
4 |
S |
$261.57 |
$830,360 |
D/D |
(3,174) |
0 |
|
-22% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2025-06-17 |
4 |
S |
$256.49 |
$374,473 |
D/D |
(1,460) |
0 |
|
-24% |
|
| Wang Lai |
Global Head of R&D |
• – – |
2025-06-17 |
4 |
S |
$251.37 |
$118,142 |
D/D |
(470) |
0 |
|
-24% |
|
| Wu Xiaobin |
President and COO |
• – – |
2025-06-17 |
4 |
S |
$250.87 |
$158,047 |
D/D |
(630) |
0 |
|
-24% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2025-06-16 |
4 |
S |
$266.05 |
$979,046 |
D/D |
(3,680) |
1,460 |
|
-19% |
|
| Wang Lai |
Global Head of R&D |
• – – |
2025-06-16 |
4 |
S |
$266.40 |
$313,558 |
D/D |
(1,177) |
470 |
|
-19% |
|
| Lee Chan Henry |
SVP, General Counsel |
• – – |
2025-06-16 |
4 |
S |
$266.50 |
$112,463 |
D/D |
(422) |
0 |
|
-19% |
|
| Wu Xiaobin |
President and COO |
• – – |
2025-06-16 |
4 |
S |
$265.47 |
$409,694 |
D/D |
(1,543) |
630 |
|
-19% |
|
| Ball Titus B. |
Principal Accounting Officer |
• – – |
2025-06-11 |
4 |
S |
$258.36 |
$34,620 |
D/D |
(134) |
0 |
|
-20% |
|
| Wang Lai |
Global Head of R&D |
• – – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
86,359 |
1,058,304 |
|
- |
|
666 Records found
|
|
Page 1 of 27 |
|
|
0.30 (0.1%) 
